Stephens analyst Sudan Loganathan raised the firm’s price target on Pyxis Oncology (PYXS) to $8 from $5 and keeps an Overweight rating on the shares, citing “growing conviction” around MICVO and its potential to be a competitive treatment option for recurrent or metastatic head and neck squamous cell carcinoma.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PYXS:
- Pyxis Oncology Reports Increased Losses Amid Development Focus
- Promising Efficacy of Pyxis Oncology’s MICVO in HNSCC Justifies Buy Rating Despite Financial Constraints
- Buy Rating for Pyxis Oncology: Promising Clinical Data and Strong Financial Position
- Promising Developments in Pyxis Oncology’s MICVO Drive Buy Rating
- Pyxis Oncology reports Q3 EPS (35c), consensus (34c)